Filament Health Corp. announced that it will supply psilocybin for two clinical trials which have received The Canadian Institutes of Health Research (CIHR) Operating Grants for Psilocybin-assisted Psychotherapy for Mental Health and Substance Use Disorders. The clinical trials will study the effects of Filament's botanical psilocybin drug candidate, PEX010, for alcohol use disorder and treatment resistant depression.

In May 2022, the CIHR announced funding to support clinical trial research into the safety and early efficacy of using psilocybin, in combination with a psychotherapy, to treat substance use and mental health disorders. On June 29, 2023, the CIHR revealed that grants have been awarded to Dr. Leah Mayo of the University of Calgary to study alcohol use disorder, and Dr. Joshua Rosenblatt at the University Health Network to study treatment resistant depression.